RxDoctor Payments DataLook up a doctor →

Howard Sofen, MD

Dermatology · Los Angeles, CANPI 1124026554

Payments from drug & device makers

$16,120,222in general payments, 2019–2025

Across 2,903 payments — averaging $5552.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$3.7M
  • Amgen$2M
  • E.r. Squibb & Sons, L.L.C.$1.9M
  • AbbVie$1.6M
  • Boehringer Ingelheim$1.6M
  • Incyte Corporation$1.6M
  • plus $3.8M from 47 others
$173,439in research payments, 2019–2025

Across 48 payments — averaging $3613.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bristol Myers Squibb$128K
  • Eli Lilly$28K
  • Amgen$11K
  • AbbVie$3K
  • Novartis$2K
  • Sanofi US Services Inc.$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly130$3,663,774
Amgen63$1,982,896
E.r. Squibb & Sons, L.L.C.100$1,878,077
AbbVie318$1,633,563
Boehringer Ingelheim44$1,561,408
Incyte Corporation628$1,560,929
Sanofi US Services Inc.55$764,030
Sun Pharmaceutical Industries Inc.227$616,017
UCB SA47$565,225
LEO Pharma AS84$469,113
Janssen Research & Development, LLC46$379,159
Dermavant Sciences, Inc.651$284,703
Kiniksa Pharmaceuticals, Ltd.62$188,594
Dermira, Inc.35$115,686
Boehringer Ingelheim International GmbH64$65,604
Merck10$50,946
Dr.reddy's Laboratories,inc.7$45,330
Bristol Myers Squibb12$38,006
Pfizer23$35,877
UCB, Inc.33$28,887
Astrazeneca UK Limited3$24,961
Novartis24$22,581
Acrotech Biopharma Inc.6$22,370
Kiniksa Pharmaceuticals International, PLC1$21,270
Biogen6$16,025
Galderma Laboratories, L.p.18$14,330
Aclaris Therapeutics, Inc.9$12,835
Boehringer Ingelheim Pharma GmbH & Co.kg35$12,066
LEO Pharma Inc.15$7,392
Hoffmann-la Roche Limited7$6,217
Boehringer Ingelheim Espana S.A.6$4,740
Gilead1$4,368
Genentech, Inc.2$4,340
Sanofi10$3,667
VYNE Pharmaceuticals Inc.1$3,025
UCB Biosciences Inc.16$2,401
Almirall LLC7$2,119
Kadmon Corporation LLC2$1,850
Boehringer Ingelheim Canada Ltd.ltee3$1,263
F. Hoffmann-la Roche AG2$1,108
UCB GmbH10$947
Regeneron Healthcare Solutions, Inc.24$874
Johnson & Johnson18$498
Genentech USA, Inc.15$291
Sanofi-aventis U.S. LLC5$203
Lilly USA, LLC7$196
Ortho Dermatologics, A Division Of Bausch Health US, LLC4$169
Revance Therapeutics, Inc.1$119
Regeneron1$68
Arcutis Biotherapeutics, Inc.2$37
Biofrontera Inc.1$26
Organon1$25
Smith+Nephew1$16

How this compares

$16,120,222 in reported general payments places this provider in the 95th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California

Medicare billing

Part B allowed, 2024
$118,500
Medicare patients
211
Services billed
1,159

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other dermatology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →